Medical Gas Plasma Jet Technology Targets Murine Melanoma in an Immunogenic Fashion
Medical Gas Plasma Jet Technology Targets Murine Melanoma in an Immunogenic Fashion
复制标题
DOI：
10.1002/advs.201903438
复制
发表时间：
2020-03-30
期刊：
影响因子：
15.1
通讯作者：
Schmidt, Anke
中科院分区：
文献类型：
--
作者：
Bekeschus, Sander;Clemen, Ramona;Schmidt, Anke
物理学的医学技术在许多类型疾病的诊断和治疗中是必不可少的。2013年，一种新颖的冷物理等离子体治疗概念被认可用于临床治疗。这种气体等离子体射流技术产生大量不同的活性氧和氮物质（ROS）。使用黑色素瘤模型，气体等离子体技术作为一种新型抗癌剂进行了测试。等离子体技术衍生的ROS在体外和体内抑制肿瘤生长。改变进料气体混合物改变ROS的组成。富含原子氧的条件与杀伤活性相关，并提高CD 8（+）细胞毒性T细胞和树突状细胞的肿瘤内免疫浸润。用B16黑素瘤细胞离体刺激的这些小鼠的次级淋巴器官的T细胞也显示出更高的活化水平。这与免疫原性癌细胞死亡和更高的钙网蛋白和热休克蛋白90的表达诱导的气体等离子体治疗黑色素瘤细胞。为了测试气体等离子体处理的黑素瘤细胞的免疫原性，与分别为1/6和5/6的小鼠阴性对照（丝裂霉素C）和阳性对照（米托蒽醌）相比，用这些细胞接种的50%的小鼠被保护免于肿瘤生长。气体等离子体射流技术的结论是提供免疫保护，对恶性黑色素瘤在体外和体内。
Medical technologies from physics are imperative in the diagnosis and therapy of many types of diseases. In 2013, a novel cold physical plasma treatment concept is accredited for clinical therapy. This gas plasma jet technology generates large amounts of different reactive oxygen and nitrogen species (ROS). Using a melanoma model, gas plasma technology is tested as a novel anticancer agent. Plasma technology derived ROS diminish tumor growth in vitro and in vivo. Varying the feed gas mixture modifies the composition of ROS. Conditions rich in atomic oxygen correlate with killing activity and elevate intratumoral immune-infiltrates of CD8(+) cytotoxic T-cells and dendritic cells. T-cells from secondary lymphoid organs of these mice stimulated with B16 melanoma cells ex vivo show higher activation levels as well. This correlates with immunogenic cancer cell death and higher calreticulin and heat-shock protein 90 expressions induced by gas plasma treatment in melanoma cells. To test the immunogenicity of gas plasma treated melanoma cells, 50% of mice vaccinated with these cells are protected from tumor growth compared to 1/6 and 5/6 mice negative control (mitomycin C) and positive control (mitoxantrone), respectively. Gas plasma jet technology is concluded to provide immunoprotection against malignant melanoma both in vitro and in vivo.